The role of histone deacetylases in inflammatory respiratory diseases: an update.

IF 3.9 3区医学 Q2 IMMUNOLOGY Expert Review of Clinical Immunology Pub Date : 2024-06-04 DOI:10.1080/1744666X.2024.2363803

Sicen Pan, Xiangdong Wang, Jian Jiao, Luo Zhang

{"title":"The role of histone deacetylases in inflammatory respiratory diseases: an update.","authors":"Sicen Pan, Xiangdong Wang, Jian Jiao, Luo Zhang","doi":"10.1080/1744666X.2024.2363803","DOIUrl":null,"url":null,"abstract":"Introduction: Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysine residues of histones and other proteins, generally leading to a closed chromosomal configuration and transcriptional repression. Different HDACs have distinct substrate specificities and functions in different biological processes. Accumulating evidence indicates that HDACs play a key role in the pathogenesis of multiple respiratory diseases.Areas covered: After an extensive search of the PubMed database, Web of Science and ClinicalTrials.gov, covering the period from 1992 to 2024, this review summarizes recent advances in understanding the role of HDACs in inflammatory respiratory diseases, including allergic rhinitis (AR), chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD). We also examine recent progress on the efficacy and potential use of histone deacetylase inhibitors (HDACi) for the treatment of these diseases.Expert opinion: Available data indicate that HDACs play an important role in the development of common inflammatory respiratory diseases, and HDACi have shown promise as treatments for these diseases. However, the exact roles and underlying mechanisms of specific HDACs in disease pathogenesis require further study. Additional work is necessary to develop novel potent HDACi with high isoform selectivity.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2024.2363803","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysine residues of histones and other proteins, generally leading to a closed chromosomal configuration and transcriptional repression. Different HDACs have distinct substrate specificities and functions in different biological processes. Accumulating evidence indicates that HDACs play a key role in the pathogenesis of multiple respiratory diseases.

Areas covered: After an extensive search of the PubMed database, Web of Science and ClinicalTrials.gov, covering the period from 1992 to 2024, this review summarizes recent advances in understanding the role of HDACs in inflammatory respiratory diseases, including allergic rhinitis (AR), chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD). We also examine recent progress on the efficacy and potential use of histone deacetylase inhibitors (HDACi) for the treatment of these diseases.

Expert opinion: Available data indicate that HDACs play an important role in the development of common inflammatory respiratory diseases, and HDACi have shown promise as treatments for these diseases. However, the exact roles and underlying mechanisms of specific HDACs in disease pathogenesis require further study. Additional work is necessary to develop novel potent HDACi with high isoform selectivity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

组蛋白去乙酰化酶在呼吸系统炎症性疾病中的作用：最新进展。

简介组蛋白去乙酰化酶（HDACs）催化组蛋白和其他蛋白质赖氨酸残基上乙酰基的去除，通常会导致染色体结构封闭和转录抑制。不同的 HDAC 具有不同的底物特异性，在不同的生物过程中发挥不同的功能。越来越多的证据表明，HDACs 在多种呼吸系统疾病的发病机制中发挥着关键作用：本综述广泛搜索了 PubMed 数据库、Web of Science 和 ClinicalTrials.gov，时间跨度从 1992 年到 2024 年，总结了在了解 HDACs 在炎症性呼吸道疾病（包括过敏性鼻炎 (AR)、慢性鼻窦炎 (CRS)、哮喘和慢性阻塞性肺病 (COPD)）中的作用方面取得的最新进展。我们还研究了组蛋白去乙酰化酶抑制剂（HDACi）在治疗这些疾病的疗效和潜在用途方面的最新进展：现有数据表明，组蛋白去乙酰化酶在常见呼吸系统炎症性疾病的发病过程中发挥着重要作用，而组蛋白去乙酰化酶抑制剂有望成为治疗这些疾病的药物。然而，特定 HDACs 在疾病发病机制中的确切作用和内在机制还需要进一步研究。开发具有高同工酶选择性的新型强效 HDACi 还需要更多的工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.